Zytiga
NICE rejects Sanofi’s Jevtana
January 12, 2012Sales and Marketing Jevtana, NICE, Sanofi, Zytiga
NICE is not recommending Sanofi’s prostate cancer drug Jevtana due to its high cost and questions over its safety. In …
Key product launches of 2011
December 19, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Actos, Benlysta, Brilique, Eliquis, Eylea, Incivek, Jevtana, Multaq, Victrelis, Xalkori, Yervoy, Zytiga, avastin, gilenya, key products
Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …
Janssen’s Zytiga launched in the UK
September 21, 2011Sales and Marketing Zytiga, prostate cancer
Janssen’s new advanced prostate cancer treatment Zytiga has been launched in the UK. Zytiga (abiraterone acetate) has been shown in …
European approval for prostate cancer drug Zytiga
September 8, 2011Sales and Marketing Janssen, Jevtana, Johnson & Johnson, Zytiga, prostate cancer
Johnson & Johnson’s Zytiga has been approved in the EU for late-stage prostate cancer. Zytiga (abiraterone acetate) is now licenced …
Janssen’s prostate cancer drug gains European backing
July 26, 2011Sales and Marketing Zytiga, prostate cancer
Janssen’s prostate cancer treatment Zytiga has been recommended by Europe’s CHMP, paving the way for possible third quarter launch. The …
NICE to appraise hep C drugs Victrelis and telaprevir
May 26, 2011Sales and Marketing Brinavess, Ilaris, NICE, Victrelis, Xarelto, Zytiga, telaprevir
NICE’s next round of drug appraisals is set to include two new hepatitis C drugs – Merck Sharpe and Dohme’s …
Prostate cancer drug Zytiga gains US approval
May 5, 2011Sales and Marketing Centocor Ortho Biotech, Johnson & Johnson, Zytiga, prostate cancer
Zytiga a new treatment for the most hard to treat cases of prostate cancer has been approved in the US. …
Latest content
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader
